Naushad Chaudhary

A couple of clarifications. First on the export side, you have mentioned there was some shipment deferment. If can you share the quantum of this shipment deferment and what was the reason for this?

On the biologics side, can you share the revenue share from the biologics product in this quarter versus last year same quarter?

Last, on the capex run rate, though you have shared in bits and pieces about different projects in detail. But if I have to -- in a simplified way, if I have to look at the company ’s total capex outlay in the next 3 years, any number if you can quantify how much we have in mind to deploy?

Two clarifications. First on the margin side, I just wanted to reconfirm on the margin profile of export business because in the past, in our multiple interactions, what we could have understood, there is a few percentage difference between export and domestic margins. Has that gap narrowed or is there a case or that in future this gap can narrow or if you can comment qualitatively on this, please?

Yes, and if there is a gap, can…

I understood, sir. Thank you for this. And second, on our newly launched 9(3) and the pipeline which we have, if you can highlight which all key crops are we targeting or focusing or how do we decide which products we have to get in? Do we decide by the crops we want to focus on or is it purely based on the availability and the performance of the product? How do we decide the product?

Hi, thanks for the opportunity. A few clarification. On the R&D side, if you can share how much we have spent in this financial year on R&D? The recurring...

Rs. 5.5 crores. And we have roughly 90 staffs in R&D, right?

Rs. 5.5 crores, this entire is recurring expenditure, right?